Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML	Acute Myeloid Leukemia With FLT3/ITD Mutation	Recruiting	Phase 1	2025-12-05		NCT05024552

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
H. Lee Moffitt Cancer Center and Research Institute	162
Jazz Pharmaceuticals	60

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Moffitt Cancer Center	Tampa	United States	523

Clinical trials